The analysis originates from neoepitope prediction based on the patient’s tumor sequencing data. A tumor sample is obtained by a biopsy. From there, genes and variants expressed in the patient’s tumor sample are selected and further optimized to produce a stable and efficient peptide. The sequences that correspond to peptides that would b
The analysis originates from neoepitope prediction based on the patient’s tumor sequencing data. A tumor sample is obtained by a biopsy. From there, genes and variants expressed in the patient’s tumor sample are selected and further optimized to produce a stable and efficient peptide. The sequences that correspond to peptides that would best bind to different HLA class I and II molecules are prioritized for synthesis.
The PanAm VAX vaccine is a peptide-based vaccine with a singular purpose, to help the immune system identify markers specific to blood vessels that feed tumors.
While it is an off-the-shelf product, the peptides used in the production of this vaccine are found in around 98% of all tumor-related blood vessels, making it an efficient way to
The PanAm VAX vaccine is a peptide-based vaccine with a singular purpose, to help the immune system identify markers specific to blood vessels that feed tumors.
While it is an off-the-shelf product, the peptides used in the production of this vaccine are found in around 98% of all tumor-related blood vessels, making it an efficient way to help diminish blood flow, and inhibiting a tumor’s ability to protect itself from the immune system.
In cutting off a tumor’s blood supply, it will undergo oxidative stress and become more susceptible to attack by the immune system due to its weakened state.
This proprietary placenta-derived vaccine affords us the ability to train the immune system to recognize and selectively destroy tumor blood vessels exclusively. This is a second-generation vaccine that has undergone rigorous clinical testing and has shown to be effective in a variety of solid tumor applications.